Top life sciences deals of 2025 show where capital is moving
VERSION 1 — BRIEF
A new PharmaShots report, produced with DealForma data, ranks the top 20 life sciences deals of 2025 and points to a market shaped by a rebound in large biopharma transactions and a strong appetite for platform technologies, oncology assets, and late-stage or commercial products. The list’s biggest deals include GSK’s July 28, 2025 collaboration with Jiangsu Hengrui Pharma, valued at about $12.5 billion and covering up to 12 programs across respiratory, immunology and inflammation, and oncology; Takeda’s October 21, 2025 oncology partnership with Innovent Biologics, valued at about $11.4 billion; and BioNTech’s June 2, 2025 strategic partnership with Bristol Myers Squibb for BNT327, valued at about $11.1 billion. The ranking also includes transactions tied to AI, data infrastructure, rare disease, and cross-border licensing, underscoring how 2025 dealmaking extended beyond traditional single-asset biotech bets. PharmaShots’ separate Top 20 Healthcare IPOs of 2025 report points in a similar direction, highlighting continued investor appetite for AI-enabled healthcare, precision medicine, diagnostics, digital care, and scaled revenue-generating platforms; the biggest raises were led by Medline Industries at $7.2 billion, followed by Caris Life Sciences at $494 million and Lumexa Imaging at $462.5 million. (linkedin.com)
Why it matters: For veterinary professionals, the direct clinical impact is limited, but the financing signals are still worth watching. Human health dealmaking often shapes where platform innovation, manufacturing capacity, diagnostics infrastructure, and specialty commercialization resources flow next. DealForma says global healthcare and life sciences M&A rose to 585 transactions worth $269.3 billion in 2025, nearly double 2024 by announced value, with activity concentrated in biopharma, diagnostics, and data-driven services. Other capital pools were growing too: Blackstone closed its BXLS VI fund at $6.3 billion, calling it the largest life sciences vehicle of its kind and reinforcing continued institutional interest in drug, medtech, and royalty-backed investing. That kind of capital rotation can influence adjacent animal health opportunities, especially in oncology, biologics manufacturing, AI-enabled R&D, diagnostics, and specialty therapeutics that may eventually spill over into veterinary innovation or partnership models. (dealforma.com)
What to watch: Watch whether this 2025 surge in large cross-border licensing, IPO, and platform deals carries into 2026, especially in areas like oncology, rare disease, AI-enabled discovery, precision diagnostics, and data infrastructure that could have downstream relevance for animal health. It is also worth watching whether private-capital interest in specialty and rare-disease businesses stays strong; for example, PharmaShots reported that CVC Capital Partners proposed a roughly €10.9 billion acquisition of Recordati, a company that had expanded its rare-disease footprint through the 2021 EUSA Pharma acquisition. (dealforma.com)